본문 바로가기
주식/개별종목

텔라닥 TDOC 2021 1분기 어닝

by Scharf 2021. 4. 29.

 

 

seekingalpha.com/news/3687290-teladoc-health-eps-misses-0_72-beats-on-revenue?utm_source=webull.com&utm_medium=referral

 

 

 

reports 1Q21 EPS of $(1.31) [down 227.5% y/y] vs est of $(0.62) [miss by 111.29%] &

Revs of $453.68M [up 150.93% y/y] vs est of $451.92M [best by 0.39%].

 

Rev segments: - Access Fee: $388.156M [up 183% y/y] -

 

Visit Fee: $54.462M [up 24% y/y] - Other: $11.057M [new line item]

 

Total Cash: $722.6M

Total Visits: 3.19M [up 56% y/y]

Total US Paid Membership: 51.5M [up 20% y/y]

 

Adj'd Gross Margin: 67.8% in 1Q21 vs 60% in 1Q20

 

Guides 2Q21 Revs of $495-$505M vs est of $486.23M

Guides 2Q21 Total Visits of 3.2M-3.4M

Guides 2Q21 Total US paid membership of 52M-53M

 

 

Guides FY21 Revs of $1.97B-$2.02B vs est of $1.99B

Guides FY21 Total Visits of 12.5M-13.5M

Guides FY21 Total US paid membership of 52M-54M

 

 

 

 

매출에서는 어닝비트 주당 순이익은 어닝 미스

 

리봉고 인수로 인한 출혈을 아직 매우기 힘든듯

 

가이던스는 살짝 상향조정

 

장기투자로는 아직 매력적이나 흑자전환까지 시간이 상당히 오래 걸릴것으로 보임

댓글